NVNO

+ Watchlist + Portfolio

enVVeno Medical Corp.

Regulated industry Physical products Sells to businessesTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $8.33
52-Week Range: $7.01 – $35.18
Market Cap: $5.63M
P/E (TTM): —
EPS (TTM): -24.99
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 0.26
PEG Ratio: —
Return on Equity: -58.53%
Return on Assets: -36.68%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 11.70
Debt/Equity: 0.02
Total Debt: $505.00K
Free Cash Flow: $-9.59M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $-15.45M

NVNO Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$9.91M	$13.58M	$12.25M	$9.98M
Selling, General & Admin	$15.02M	$11.65M	$11.58M	$10.92M
Operating Expenses	$24.93M	$25.24M	$23.83M	$20.90M
Operating Income	-$24.93M	-$25.24M	-$23.83M	-$20.90M
EBITDA	-$24.41M	-$24.69M	-$23.30M	-$20.41M
Pretax Income	-$24.67M	-$23.52M	-$21.82M	-$19.47M
Net Income	-$24.67M	-$23.52M	-$21.82M	-$19.47M
Diluted EPS	-77.00	-66.85	-44.53	-33.06
Diluted Shares	320857	351457	489999	588999

NVNO Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$4.55M	$3.62M	$1.75M	$3.06M
Current Assets	$39.44M	$46.92M	$43.73M	$28.83M
Total Assets	$41.66M	$48.63M	$44.95M	$29.56M
Current Liabilities	$1.53M	$1.37M	$2.10M	$2.12M
Total Debt	$1.72M	$1.40M	$1.06M	$700.00K
Total Liabilities	$2.93M	$2.44M	$2.79M	$2.43M
Retained Earnings	-$106.52M	-$130.04M	-$151.85M	-$171.33M
Shareholders' Equity	$38.73M	$46.20M	$42.16M	$27.13M
Working Capital	$37.91M	$45.55M	$41.64M	$26.70M

NVNO Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$15.62M	-$18.86M	-$16.84M	-$15.57M
Capital Expenditure	-$115.00K	-$33.00K	-$37.00K	-$5.00K
Free Cash Flow	-$15.73M	-$18.89M	-$16.88M	-$15.57M
Depreciation & Amortisation	$525.00K	$546.00K	$528.00K	$489.00K
Stock-Based Compensation	$8.99M	$5.20M	$4.14M	$3.42M
Investing Cash Flow	-$34.55M	-$7.87M	$1.33M	$15.86M
Financing Cash Flow	$0.00	$25.79M	$13.64M	$1.02M
Net Change in Cash	-$50.17M	-$935.00K	-$1.87M	$1.31M

NVNO Income statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$2.89M	$2.58M	$1.95M	$2.11M	$2.08M
Selling, General & Admin	$4.16M	$2.30M	$2.06M	$1.95M	$1.72M
Operating Expenses	$7.05M	$4.88M	$4.01M	$4.06M	$3.80M
Operating Income	-$7.05M	-$4.88M	-$4.01M	-$4.06M	-$3.80M
EBITDA	-$6.92M	-$4.76M	-$3.90M	-$3.94M	-$3.77M
Pretax Income	-$6.69M	-$4.54M	-$3.74M	-$3.85M	-$3.60M
Net Income	-$6.69M	-$4.54M	-$3.74M	-$3.85M	-$3.60M
Diluted EPS	-11.52	-8.05	—	-5.89	-5.37
Diluted Shares	581000	575857	—	654000	671000

NVNO Balance Sheet statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$2.04M	$1.54M	$3.06M	$2.60M	$2.84M
Current Assets	$35.60M	$31.50M	$28.83M	$25.49M	$22.08M
Total Assets	$36.58M	$32.35M	$29.56M	$26.10M	$22.66M
Current Liabilities	$3.02M	$2.40M	$2.12M	$2.14M	$1.89M
Total Debt	$882.00K	$791.00K	$700.00K	$603.00K	$505.00K
Total Liabilities	$3.52M	$2.90M	$2.43M	$2.35M	$1.99M
Retained Earnings	-$163.05M	-$167.59M	-$171.33M	-$175.18M	-$178.78M
Shareholders' Equity	$33.06M	$29.45M	$27.13M	$23.75M	$20.67M
Working Capital	$32.59M	$29.10M	$26.70M	$23.35M	$20.20M

NVNO Cash Flow statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$3.71M	-$4.39M	-$3.44M	-$3.24M	-$3.55M
Free Cash Flow	-$3.72M	-$4.39M	-$3.44M	-$3.24M	-$3.55M
Depreciation & Amortisation	$130.00K	$120.00K	$117.00K	$124.00K	$29.00K
Stock-Based Compensation	$1.44M	$688.00K	$637.00K	$467.00K	$397.00K
Investing Cash Flow	$2.82M	$3.65M	$4.18M	$2.77M	$3.67M
Financing Cash Flow	$0.00	$241.00K	$782.00K	—	—
Net Change in Cash	-$893.00K	-$500.00K	$1.52M	-$468.00K	$244.00K

Market Snapshot

About

enVVeno Medical Corp. is a medical device company focused on developing and commercializing innovative solutions for venous disease. The company addresses chronic venous insufficiency, varicose veins, and related vascular conditions through minimally invasive treatment technologies. enVVeno aims to improve patient outcomes and quality of life by providing safer, more effective alternatives to traditional venous therapies.